ZUPLENZ - (4MG, 8MG ; Film)

Generic Name	ONDANSETRON	**Innovator**	AQUESTIVE
Dosage	4MG, 8MG ; Film	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	ZUPLENZ is a 5-HT3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2, in adults. • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy in adults and pediatric patients 4 years of age and older. • nausea and vomiting associated with radiotherapy in adult patients receiving either total body irradiation, single high-dose fraction to abdomen, or daily fractions to the abdomen. • postoperative nausea and/or vomiting in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.